

## Outstanding Start for Hybrigenics' 2009 Revenues:

### Cancer treatment specialist almost triples Q1 sales

**Paris, 02 June 2009** – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments and specialised in protein interactions, today announces its sales and revenues for the first quarter 2009.

EUR (Thousands)	1Q2009	1Q2008	Change %
<b>Sales</b>	<b>1,130</b>	408	+177%
<i>Pharma</i>	<i>400</i>	-	<i>na</i>
<i>Services</i>	<i>730</i>	408	+79%
<i>Other operating revenues</i>	<i>141</i>	119	+18%
<b>Total operating revenues</b>	<b>1,271</b>	527	+141%

Hybrigenics Services' sales increased by +79% in 1Q2009 as compared with 1Q2008. The renewal of the Pharma research collaboration with Servier on a specific confidential ubiquitin-specific protease involved in cancer was signed earlier in 2009 and has already triggered a first payment of EUR 400,000.

"The demand for Hybrigenics' highly sophisticated protein interaction yeast two-hybrid technology seems, for the moment, to be resistant to the current economic downturn", said Remi Delansorne, Hybrigenics' CEO. "In addition, we are delighted by the renewed confidence of Servier in our expertise in ubiquitin-specific proteases applied to oncology."

#### About Hybrigenics

Hybrigenics ([www.hybrigenics.com](http://www.hybrigenics.com)) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics' development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis' Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.

Hybrigenics is also the market leader in Yeast-Two Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

\*\*\*

# HYBRIGENICS

Press Release

**Hybrigenics**  
**Rémi Delansorne**  
Directeur Général  
Tél. : +33 (0)1 58 10 38 00  
investors@hybrigenics.com

**NewCap.**  
Communication financière  
Axelle Vuillermet / Pierre Laurent  
Tél. : +33 (0)1 44 71 94 94  
hybrigenics@newcap.fr